InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU

Reuters

2025/11/10

InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU

InflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582765498"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582765498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582765498?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582765498","market":"us","top_or_hot":-1,"title":"InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IFRX\">InflaRx N.V.</a> has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IFRX\">InflaRx N.V.</a> has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbGbyMg:1","article_id":"2582765498","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582765498","pubTimestamp":1762778223,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa  and chronic spontaneous urticaria . The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score  and improvements in the Urticaria Control Test . InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IFRX":"InflaRx N.V."},"translate_title":"InflaRx报告INF904在HS和CSU中的阳性2a期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":0.9},"content_text":"InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU\n    \n\nInflaRx N.V. has announced positive topline data from a Phase 2a basket study evaluating its anti-inflammatory therapeutic candidate, INF904, in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study reported efficacy data from 29 of 31 HS patients and 30 of 31 CSU patients, with further results expected after completion of a 4-week post-treatment observation period. In CSU patients, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) and improvements in the Urticaria Control Test (UCT7). InflaRx plans to initiate a Phase 2b trial in HS in 2026 and continues to enroll patients in a third CSU dosing cohort. Final results from the Phase 2a study are scheduled for presentation at upcoming major scientific meetings. The company hosted a webcast to discuss the topline data and will hold additional events to further showcase INF904.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}